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Abstract
Although the number of iodine-deficient countries has been reduced by almost 50 % over the last decade, it still remains a frequently mis-
understood health problem. The most devastating effects of iodine deficiency occur during fetal development and childhood, periods in
which sufficient iodine delivery remains critical. Besides the determination of thyroid size, the concentration of urinary iodine, serum
thyroid-stimulating hormone and serum thyroglobulin are useful biomarkers to assess iodine status. Severe iodine deficiency is associated
with neurological complications, cretinism, endemic goitre development, hypothyroidism, decreased fertility and increased infant mortality.
The recommended iodine supplementation strategies are based on correction of iodine deficiency, close monitoring and evaluation of
iodine administration, cooperation of the salt industry, training of local health care professionals and education of the population. Besides
the multiple beneficial effects of supplementation, we present in this review a critical look at the possible side effects.
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Although the presence of iodine in the thyroid was already
discovered in 1895 by Bauman(1), it took until 1917 before
Marine & Kimball(2) could make the connection between
iodine deficiency and the occurrence of goitre. An estimated
200–300 million people presently suffer from some form of
iodine deficiency, mainly in Asia and Africa, but also in
large parts of Eastern Europe(3). Multiple studies have empha-
sised the influence of ethnicity and seasonality on iodine
status(4–6). In general, iodine deficiency in a population is
associated with subtle, negative effects: a decreased level of
education, reduced work productivity and apathy, disrupted
economic and social development. As mild-to-moderate
iodine deficiency affects 30 % of the total population and
may impair cognitive development in children, iodine
deficiency is considered as the most common cause of preven-
table mental retardation worldwide(7). Adequate iodine intake
is particularly important in vulnerable groups, such as preg-
nant women, lactating women and infants(8). Given the fact
that a lack of this essential nutrient is the main cause of
preventable brain damage, universal iodine supplementation
is part of many national nutritional strategies(9). Mild iodine
deficiency is associated with a higher prevalence of auton-
omous thyroid nodules and multinodular goitre, which are
the main causes of hyperthyroidism in the adult popu-
lation(10). The purpose of the present study was to give an
overview of the important role of iodine supplementation
without forgetting the pitfalls.
Epidemiology
The prevalence of iodine deficiency is mainly based on data
from urinary iodine levels in school children, which generally
reflects the status of the entire population(11). However, some
authors found major differences in the nutritional profile of
children and adults, suggesting that the outcome of the earlier
studies might not present an accurate picture of iodine
deficiency in the whole population(6). The total prevalence
of goitre is not sufficiently sensitive to recent changes in
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iodine intake. In 2007, the WHO reported that nearly 2 billion
individuals worldwide (36·5 % of school-age population and
35·3 % of the general population) had insufficient iodine
intake, including one-third of all school-age children. Until
recently there was no system for monitoring iodine deficiency.
Unlike the USA, where .90 % of the households use iodised
salt, European countries are characterised by a high degree
of iodine deficiency (^60 %). Implementation of structured
iodine supplementation programmes led to a turnaround in
2003, with a decline in the proportion of school-going
children at risk(3). Presently, the prevalence of goitre globally
is 15·8 %, with the highest frequency in the Eastern Mediterra-
nean (37·3 %) and the lowest in the USA (4·7 %)(12). The
interpretation of the WHO data should be done with caution.
Representative (sub)national studies covering 60 % of the
global population can underestimate or overestimate the
extent of iodine deficiency. Extrapolation of a population indi-
cator (the median urinary iodine content) to define the
number of affected individuals is also not so accurate(3).
Finally, there are insufficient data available to estimate the
prevalence of this health problem in pregnant women(13).
Polymorphism
Although iodine supplementation will aid significantly in ame-
liorating thyroid problems, evolutionary pressure should also
be taken into account. Strong selective pressures in the past
have shaped our ability to detect anti-thyroid compounds
and to avoid them(14). Food preferences are influenced by a
number of factors such as personal experiences, cultural adap-
tations and perceived health benefits. Based on the response
to bitter-tasting compounds such as phenylthiocarbamide
(PTC) or 6-n-propylthiouracil, individuals can be classified
as supertasters (30 % of the world’s population), tasters
(50 % of the world’s population) or non-tasters (20 % of the
world’s population)(15–21). The prevalence of taste insensitiv-
ity to PTC and 6-n-propylthiouracil varies in human popu-
lations: Indians: 40 %, Caucasians: 30 %, Chinese: 6–23 % and
West Africans: 3 %(22–23). Bitter substances bind to approxi-
mately thirty human taste receptors type 2, residing on the
surface of the taste cells within the taste buds of the tongue.
Those receptors belong to the heptahelical or G protein-
coupled receptor (GPCR) family, characterised by the
presence of seven transmembrane helices and the interaction
with intracellular G proteins(24–26). Activation of the G
protein-coupled receptor signalling pathways leads to bitter
perception(27). Polymorphisms of the TAS2R38 gene (located
in a small region on chromosome 7q) account for 55–85 %
of the variance in PTC sensitivity, which is almost completely
explained by amino acid substitutions at position 49 (alanine
or proline), 262 (valine or alanine) and 296 (isoleucine
or valine)(28). This gives rise to two major haplotypes (proline–
alanine–valine (the taster variant) and alanine–valine–
isoleucine (the nontaster variant)) and three less common
variants, which are either rare (alanine–alanine–valine and
proline–valine–isoleucine) or limited to specific populations
(alanine–alanine–isoleucine in sub-Saharan Africans)(29). Sub-
jects, homozygous for the proline–alanine–valine haplotype
are most sensitive to the taste of PTC or 6-n-propylthiouracil;
those who are homozygous for the alanine–valine–isoleucine
haplotype are least sensitive while individuals who carry a
copy of both haplotypes (proline–alanine–valine/alanine–
valine–isoleucine) have an intermediate sensitivity(30–31).
As PTC-related substances show anti-thyroid activity, a sig-
nificant excess of non-tasters with non-toxic goitre has been
reported in communities with endemic goitre(16,20,21,32). Inges-
tion of glucosinolates in plants inhibits thyroid peroxidase
activity and blocks active transport of iodide into the thyroid,
resulting in both retarded sexual maturation and mental retar-
dation in low iodine regions(33–35). After iodine supplemen-
tation, the described association is no longer observed.
It has been suggested that PTC polymorphism is conserved
in human beings as a protective mechanism against the
overconsumption of dietary goitrogens(32).
Detection methods for iodine deficiency
Four complementary indicators are available for determining
iodine status: urinary iodine concentration (UI), thyroid size,
serum thyroid-stimulating hormone (TSH) and thyroglobulin
(Tg). UI is a sensitive biochemical marker of recent iodine
intake (d)(36). A simple spot urine sample collected from a
representative sample is sufficient to measure iodine output
(mg/l). Although the median UI gives no direct information
on the thyroid function, a low value is an indication of an
increased risk for thyroid problems(37). Iodine excretion may
vary on a daily basis, intra-/inter-individually and among
different population groups(38). The thyroid size is primarily
determined by inspection and palpation (grade 0–2). Despite
the advantages (non-invasive and quick to implement), the
reliability of this method is limited by high inter- and intra-
observer variations. An additional ultrasound of the thyroid,
taking into account the international reference ranges for a
normal thyroid size in iodine-sufficient children, is rec-
ommended. Changes in goitre development reflect long-term
iodine nutrition (months to years)(39). Serum TSH is depen-
dent on serum concentration of the circulating thyroid hor-
mone. Although slightly elevated levels are observed in
iodine-deficient populations, the majority of school children
and adults present normal TSH concentrations. The increase
in the number of neonates with moderately elevated TSH con-
centrations (.5 mIU/l in whole blood) is proportional to the
degree of iodine deficiency(37,40–42). Serum Tg concentrations
are increased in thyroid hyperplasia and after TSH stimulation.
There is a good correlation with the degree of iodine
deficiency, measured by UI. Moreover, Tg is also a better
indicator for iodine repletion (weeks to months) compared
with TSH or T4
(43). As the widespread use of TSH and Tg in
the determination and monitoring of iodine deficiency at the
population level is still very limited, these data were not
included in the WHO database on iodine deficiency(40).
Iodine fortification and supplementation
The universal iodisation of salt (both for human and animal
consumption) is considered as the most appropriate strategy
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to address the problem of iodine deficiency. Its success has
many reasons. Salt is used by almost everyone and its intake
is even throughout the year. In most countries, the production
and import of salt are carried by a limited number of people.
The implementation of a universal salt iodisation is a larger,
but still a worthy challenge in areas with many small salt pro-
ducers. Moreover, it is a simple and cost-effective method,
with no change in colour and taste of the salt. The amount
of iodine added to salt can easily be monitored(37,44).
The WHO recommends a daily iodine intake of 90mg for
infants (0–59 months), 120mg for school-age children (6–12
years), 150mg for adolescents and adults and 200mg for preg-
nant and lactating women. Fortification of iodine to salt can
occur in the form of potassium iodide (KI) or iodate. Depend-
ing on the local salt intake, 20–40 mg iodine/kg salt is added
following the guidelines of the WHO/UNICEF/International
Council for the Control of Iodine Deficiency Disorders(3).
Environmental factors, such as the consumption of goitrogens
and a shortage of trace elements in the diet (Se and Fe), may
prevent an optimal response to administered iodine(45,46).
Alternatives to universal salt iodisation have been
described. Bread, water, irrigation water, milk and cattle feed
are vehicles for iodised salt(47–51). Iodised oil, obtained by
esterification of unsaturated fatty acids in seed or vegetable
oils, can be given daily or annually in a peroral or intramuscu-
lar administration(3,52,53). The dose is 200–400 mg iodine/year
and is primarily intended for young or pregnant women and
children(3). The administration of iodine in the form of KI
(30 mg/month or 8 mg/2 weeks) or potassium iodate drops/
tablets is another option(54). Antiseptics (Lugol solution) are
also iodine preparations(37).
In countries with an iodised salt programme, attention must
be paid to weaning infants, particularly to those not receiving
iodine-containing infant formula milk. Infants are at high risk
for iodine deficiency, because their requirements per kg body
weight for iodine and thyroid hormone are much higher than
at any other time in the life cycle(55,56). The iodine intake of
breastfed infants relies solely on the iodine concentration of
breast milk, which, in turn, reflects the mother’s iodine
status(8). The highest concentration of iodine is found in
colostrum with concentrations of 200–400mg/l, decreasing
to 50–150mg/l in mature human milk(57,58). Pre-term infant
formulas contain 20–170mg iodine/l, which may be too low in
particular situations to achieve the recommended intake of
iodine(59).
Iodine dosage via the enteral or parenteral route is efficient,
as oral iodine bioavailability is 90–95 %. However, parenteral
solutions contain much less iodine than enteral formulas.
In parenterally fed infants and children, with a daily rec-
ommended iodine dose of 1mg/kg, this 50 % iodine intake
deficit is corrected by the absorption of iodine through the skin
from topical iodinated antiseptics and by the administration of
iodine in other infusions(60,61). In iodine-sufficient adults, with
a daily iodine requirement of 70–150mg, thyroidal iodine
stores are often adequate to meet the needs of adult patients
requiring total parenteral nutrition for less than 3 months(62).
Besides iodised salt, which is the most important source of
iodine worldwide, multiple dietary sources of iodine are of
great importance for achieving a sufficient dietary iodine
intake. Dietary sources of iodine vary with country and popu-
lation(63). The native iodine concentrations in most food
groups are low. The most commonly consumed foods provide
3–80mg/serving(60). The highest content of this micronutrient
is found in milk, eggs and products of marine origin (with
higher mean iodine concentrations in lean fish species com-
pared with fatty fish species). Milk and dairy derivates contain
relatively high amounts of iodine. A seasonal variation of
iodine concentration in milk is reported with a significantly
higher iodine content of milk in the winter season, compared
with the summer season. This finding can be explained by the
use of cow fodder fortified with iodine during winter. The
average iodine content within the same season is comparable
for different types of milk(63). In a group of pregnant women,
a multivariate analysis showed that milk was the only variable
influencing UI, including the use of iodised salt, iodine sup-
plementation and different foods(8). Moreover, in contrast to
fish, eggs or iodised salt, a high correlation between UI,
milk and dairy products intake was reported in Italian
school children(64). Eggs, and more specifically egg yolks,
are another rich source of iodine. The content of iodine in
eggs depends on the iodine concentration in hen fodder(65).
Recently, the value of fortified eggs as a unique nutritional
supplement for peak brain development during pregnancy,
nursing and infancy was demonstrated(66).
Seafood, including saltwater fish, shellfish, kelp, seaweed
and seaweed products can provide a considerable amount
of iodine. However, its contribution depends on the alimen-
tary habits of the population(63). Iodine inhalation may influ-
ence iodine status and may help explain why despite the
absence of a regular source of dietary iodine intake such as
iodised salt, coastal communities residing in seaweed-rich
areas can maintain an adequate dietary iodine supply(67).
The mean iodine concentration in other foodstuffs (meat,
meat products, bread, cereals, vegetables, potatoes, fruits,
berries, fats and oils) is 2–3mg/100 g, which is limited in
comparison with the total iodine intake. The contribution of
iodine from drinking-water is region dependent(63). Iodine-
containing compounds used in irrigation, fertilisers, livestock
feed, dairy industry disinfectants and bakery dough condi-
tioners influence iodine content in foods(60).
Iodine supplementation by the independent administration
of KI is preferable, as a lot of multivitamin preparations do not
contain an adequate amount of iodide(67). Recent studies in
Spain have shown that only a minority of women used
iodine supplements during their pregnancy, either as iodine
or as multivitamin tablets containing 100–200mg of iodine
each. Although iodine supplementation alone was not effec-
tive, the combination of iodine supplements and a diet rich
in milk reached an acceptable median UI. Pregnant women
from an iodine-sufficient area could have a suboptimal
iodine status without a diet rich in iodine or without sup-
plementation with iodine-containing tablets(66). Apart from
universal iodisation of salt, the use of iodine supplements as
vitamin complexes or as KI tablets is recommended from
the start of gestation or earlier in the case of planned
pregnancy(68).
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Value and pitfalls
Benefits
Pre-natal iodine supplementation in severe iodine deficiency
is associated with a significant reduction in the prevalence
of endemic cretinism(69). Data from cross-sectional studies
on the relationship between iodine intake and post-natal
growth of the child are often contradictory, although most
of them describe a positive correlation(70–72). Iodine repletion
induces an increase in insulin-like growth factor 1 and insulin-
like growth factor binding protein 3 with a beneficial effect on
somatic growth in children from moderate-to-severe iodine-
deficient areas(73).
The interpretation of the results of randomised trials, which
investigate the impact of iodine supplementation studies on
the cognitive functioning of children, is hampered by meth-
odological problems(74). Targeted supplementation to preg-
nant women, living in regions with a history of even small
degrees of iodine deficiency, needs a strong implementation
of pre-conception programmes since the start of pregnancy
is often detected at a later stage(75). Iodine treatment of preg-
nant women in areas with severe deficiency reduces fetal
and perinatal mortality and improves motor and cognitive
abilities of the offspring(76,77). Adequate substitution during
the first and second trimester appears to be essential(78,79).
Pre- and post-natal iodine supplementation of Chinese chil-
dren from areas with severe iodine deficiency resulted in an
average increase of 8·7 intelligence quotient points(80). The
recommended cut-off for the median UI in lactating women
is 100mg/l based on the premise that the expression of the
sodium iodide symporter in the breast during lactation results
in dietary iodine being secreted into breast milk rather than
into urine(54,81). In countries with a sustained iodine sup-
plementation programme, newborns may not be at risk of
alterations in thyroid functions, irrespective of mothers’
UI(82). In regions with iodine deficiency, the breast-milk
iodine concentration appears to decrease over the 24-week
postpartum period, indicating that the amount of iodine in
breast-milk needs to be much higher during early lactation(8).
Several European randomised trials of iodine supplemen-
tation were carried out in mild-to-moderate iodine-deficient
pregnant women. Iodine reduced the thyroid size of the
mother and the newborn. In some cases, a decrease of
maternal TSH and Tg was observed. However, no trial
showed an effect on total or free thyroid hormone concen-
trations of the mother and the newborn. Moreover, there
was no account of the long-term clinical consequences, such
as maternal goitre, thyroid autoimmunity or the development
of the child(83–85). Thyroid autonomy is a frequent cause of
thyrotoxicosis in patients with iodine deficiency. Based on
epidemiological data, which suggest an influence of iodide
on the course of pre-existing thyroid autonomy(86), Mu¨ller
et al.(87) investigated the effect of iodine on early-stage thyroid
autonomy. In cell cultures, iodine decreases the biological
activity of autonomous thyrocytes. Iodine supplementation
prevents the development of thyroid autonomy by decreasing
the occurrence of somatic TSHR mutations and slows down
the development of clinically relevant disease. Recently, the
influence of iodine supplementation on thyroid function and
its effect on plasma markers of oxidative stress, inflammation
and acute-phase proteins was examined in a population of
healthy adults with adequate iodine intake. The administration
of 100–300mg iodine in the form of KI for 6 months did not
modify thyroid function. Moreover, a slight anti-inflammatory
and antioxidative action of iodide was demonstrated(88).
The economic advantages for health of avoiding endemic
goitre and mental retardation in the case of severe iodine
deficiency are quite obvious. In addition, implementation of
an iodisation programme in a country suffering from mild
iodine deficiency can be considered, which may prevent
hyperthyroidism by reducing the number of patients with
multinodular goitre and thyroid nodules and may improve
cognition in mildly iodine-deficient children(3,89–91).
Abundance and toxicity (Table 1)
The thyroid gland is able to adapt to different doses of iodine
to regulate the synthesis and release of thyroid hormones.
A chronic intake of 30 mg up to 2 g iodine/d is tolerated by
iodine-sufficient individuals. A persistent drop of serum T4
and T3 of 25 and 15 %, accompanied by a TSH rise of 2 mIU/l
is observed. An excessive intake of iodine may increase the
risk of autoimmune thyroiditis, hyperthyroidism (especially
in a pre-existing multinodular goitre), (sub)clinical hypothyr-
oidism (especially in a pre-existing Hashimoto’s thyroiditis)
and goitre(92,93).
One of the main side effects seen in multiple iodine
supplementation programmes concerns iodine-induced
hyperthyroidism(94–96). The risk is elevated in an initial
severe iodine deficiency, a subsequent (too) large increase
in iodine intake, a mean urinary iodine level $300mg/l and
in smokers(10,96). Especially, adults (.40 years) with a long-
standing nodular goitre are at increased risk. Given that the
symptoms of iodine-induced hyperthyroidism are not specific
enough, this problem is frequently overlooked(97). Iodine-
induced hyperthyroidism is almost always transient and the
incidence falls over time (1–10 years after the introduction
of the supplementation programme) back to its normal
level(98). An excessive intake of iodine may induce a flare of
Graves’ disease, which is age independent(99). Besides the
effect on thyroid hormone synthesis, this is most probably
due to the stimulation of the intra-thyroidal autoimmune
process. However, autonomous nodules are not the only
pathogenetic explanation for iodine-induced hyperthyroidism,
as this phenomenon was also reported in entirely normal
glands(100).
Bu¨low Pedersen et al.(101) diagnosed new cases of
hypothyroidism in addition to hyperthyroidism. Despite a
careful introduction of iodised salt, the incidence of hypothyr-
oidism slightly increased in areas with a previous moderate
iodine deficiency. Even in subjects with normal thyroid func-
tion, high iodine intake can negatively affect thyroid hormone
levels(102). Investigation of the impact of iodine intake on thyr-
oid diseases in China showed an increase in the prevalence of
overt hypothyroidism, sub-clinical hypothyroidism and
autoimmune thyroiditis with increasing iodine intake(103).
M. M. Speeckaert et al.4
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In addition, the investigators showed in a recent paper that
even a median UI of 200–300mg/l might be related to a poten-
tial increased risk of developing sub-clinical hypothyroidism
or autoimmune thyroiditis(104), which differs from the data
published by the WHO (median UI . 300mg/l)(40). The
exact mechanism by which chronic high iodine intake induces
hypothyroidism remains unclear. Iodine-induced hypothyr-
oidism usually resolves quickly after iodine withdrawal, but
if the administration of iodide continues, overt or sub-clinical
hypothyroidism will persist(105). Preventing iodine deficiency-
induced hypothyroidism is important as it is an independent
risk factor for CHD and can result in a poor neurodevelop-
mental outcome if present during pregnancy(106,107). A more
than adequate iodine intake may be a risk factor for auto-
immune thyroiditis in humans, which is reflected by the
correlation between the prevalence of positive thyroid auto-
antibodies and the amount of iodine intake. The underlying
mechanisms of this phenomenon induced by iodine intake
are: (1) an increased immunogenicity of Tg, precipitating an
autoimmune process at both the T and B-cell level; (2) a
toxic effect on thyroid cells and (3) a direct stimulation of
immune and immunity-related cells(104).
Acute iodine poisoning, which is uncommon as it usually
occurs with doses of multiple grams, is associated with gastro-
intestinal discomfort (abdominal pain, nausea, vomiting and
diarrhoea), cardiovascular symptoms, coma and cyanosis. An
excessive intake of iodine may rarely cause iodermia, a
dermatological condition comprising acneiform eruptions, an
itchy rash and urticaria(108,109). Iodine excess causes a tempor-
ary inhibition of thyroid hormone synthesis (the Wolff–Chaik-
off effect), inhibits cell growth, induces apoptosis and affects
cell morphology(110).
Although animal studies showed a significantly increased
number of thyroid carcinomas after prolonged iodine
deficiency, proof of a direct causative role for iodine
deficiency remains elusive. A review of animal experiments,
epidemiological and basic gene transfection studies showed
a weak relationship between iodine intake and cancer(111).
Table 1. Classification according to the degree of iodine deficiency
Iodine intake Iodine status Median urinary
iodine
concentration
(µg/l)
Consequences Pathophysiology
Multinodular toxic struma
Insufficient Severe iodine
deficiency
Moderate iodine
deficiency
Mild iodine
deficiency
Sufficient
Excessive
Normal iodine
status
Moderate
overdosage
Excessive
overdosage
<20
20–49
50–99
100–199
200–299
≥300
Normal T4
Goitre, multinodular toxic stroma,
increased incidence of thyroid
carcinomas
Pregnancy:
Gestational hypertension, first
trimester abortion, stillbirth,
congenital defects, impaired
mental and psychomotor
development of the fetus
Iodine
Iodine
Thyroid hyperplasia
Pr
o
lif
er
at
io
n
Low T4
Goitre
Chronic iodine deficiency:
Dyslipidaemia, insulin resistance,
subclinical inflammation
Autoimmune thyroiditis,
hypothyroidism or
hyperthyroidism, goitre, Graves'
exacerbation, decreased treatment
efficacy with radioactive iodine
Risk of adverse health consequences
(autoimmune thyroiditis,
hyperthyroidism, (sub) clinical
hypothyroidism and goitre)
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The overall incidence of differentiated thyroid carcinoma is
generally not considered to be influenced by iodine intake
of a population, whereas the distribution of the types of thyr-
oid carcinoma (papillary:follicular carcinoma ratio) seems to
be related to the intake of iodine. Papillary carcinoma is the
predominant type of thyroid malignancy in non-endemic
areas and shows an increasing incidence in goitrous regions
after iodine prophylaxis. This could be related to the long-
term effect of iodine supplementation and/or to other factors
(e.g. radiation fallout, inclusion of papillary microcarcinomas,
better access to medical care, etc.)(112–114). Iodine-deficient
regions have a tendency to show higher rates of undifferen-
tiated (anaplastic) carcinomas before iodine prophylaxis,
compared with post-prophylaxis periods and regions with
high dietary iodine intake(114).
In the treatment and follow-up of well-differentiated thyroid
cancer, a temporary low-iodine diet (LID) is generally rec-
ommended before high-dose radioactive iodine (131I) ablation
therapy or radioactive iodine scanning. The stringency and the
duration of restriction about the time of therapy are debata-
ble(115). The American Thyroid Association recommends an
LID defined by an intake of ,50mg/d for 1–2 weeks before
131I ablation(116); the British Thyroid Association recommends
an LID for 2 weeks before 131I ablation or therapy(117); the
European Thyroid Cancer Taskforce recommends an LID for
3 weeks before 131I administration(118) and the American
Association of Clinical Endocrinologists recommends con-
sumption of an LID for 2–4 weeks before radioiodine scan-
ning, with no specific recommendations on stringency or
diet before 131I treatment. It is currently not known whether
an LID may result in improved long-term outcomes in thyroid
cancer(115).
Discussion
Iodine deficiency is the leading global cause of preventable
brain damage. It remains the primary motivation behind the
present global approach to eliminating iodine deficiency.
Although multiple studies have stressed the importance of
iodine supplementation, we also need to be mindful of its
risks. The intake of iodine from a base diet varies considerably
between countries, mainly due to a different consumption of
milk and dairy products, bread, marine fish and iodised salt.
In multiple studies, the introduction of major salt iodisation
programmes was followed by a considerable decrease in the
prevalence of goitre and iodine deficiency disorders, saving
costs of curative medicine(119). Approximately, 90 % of salt
consumption in industrialised countries is obtained from pro-
cessed foods, which stresses the importance of using iodised
salt in the food industry(120). However, salt consumption
remains a risk factor for hypertension, atherosclerosis, myo-
cardial infarction, stroke and cancer. Verkaik-Kloosterman
et al. investigated the influence of a reduction in salt intake
on habitual iodine intake and subsequent consequences on
iodine levels in The Netherlands. Using a simulation model,
the investigators demonstrated that despite salt reduction in
industrially processed foods of 12, 25 and 50 %, iodine intake
remained adequate for a large part of the Dutch population.
Only up to 10 % of the subjects would be prone to an
inadequate iodine intake if both industrially and discretionary
added salt would be reduced by 50 %. The situation is differ-
ent for the group of 1- to 3-year-old children, which might
have an inadequate iodine intake below the corresponding
estimated average requirement, depending on the salt intake
scenario(121). However, there is no conflict between the efforts
to reduce salt consumption to prevent chronic diseases (even
if per capita salt intakes are reduced to ,5 g/d) and the policy
of salt iodisation to eliminate iodine deficiency(120). The use of
other iodine-rich products (e.g. milk) and iodine supplements
to achieve an adequate physiological iodine level must be pro-
moted with individual, population and regional differences in
mind(122). For instance, as a relationship between high iodine
level in drinking-water and goitre prevalence has been
reported in multiple studies, it can be important to prevent
goitre through stopping the provision of iodised salt and pro-
viding normal drinking-water iodine in some areas(123–125).
The main constraints to iodine supplementation are related
to supply and awareness of health staff and communities(125).
The potential benefits of iodine fortification and supplemen-
tation greatly outweigh the potential risks. However, increas-
ing iodine intake in deficient populations is not without risk.
Mild iodine deficiency may be associated with a decreased
risk of overt and sub-clinical hypothyroidism, as well as auto-
immune thyroiditis. A geographical difference in clinical
effects of varying iodine intake is observed, which may be
related to differences in underlying thyroid autonomy, genetic
susceptibility or other environmental variables(37,126). Efforts
to monitor iodine status and to implement adequate iodine
supplementation should be intensified in those countries
where iodine deficiency remains a public health problem.
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